Targeting Inflammatory Pathways in Atherosclerosis: Exploring New Opportunities for Treatment.

Curr Atheroscler Rep · 2024 · PMC11530513 · PMID 39404934

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

The recently published CONVINCE phase-3 trial showed a trend in MACE reduction in patients with non-embolic ischemic stroke treated with colchicine versus placebo, although the results were not statistically significant [ 52 ].

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.